Glaucoma prevalence increases as the population ages. The FDA has approved Omlonti (omidenepag isopropyl ophthalmic solution) 0.002% eye drops for the reduction of elevated intraocular pressure (IOP) in patients with primary open-angle glaucoma or ocular hypertension. These eye drops work by reducing the amount of fluid in the eye, thereby lowering intraocular pressure. Omlonti is a relatively selective prostaglandin EP2…
María RomeroApril 23, 2023